small-cell lung cancer
Conditions
Interventions
treatment group:Cisplatin 25mg/m2 was administered intravenously over 30 to 60 minuteson on day 1-3
Etoposide 120mg/m2 was administered intravenously over 60 minutes on days 1-4
Endostar 15 mg was administered over 90 minutes by IV infusion on days 1-14
Repeated every 3 weeks for up to four cycles.
Sponsors
The First College Of Clinical Medical Science, China Three Gorges University &Yichang Central People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Patients with previously untreated, histologically or cytologically confirmed ED-SCLC were eligible; age 18 years or older; measurable disease; an ECOG performance status (PS) of 0 to 2; life expectancy of greater than 12 weeks; adequate hematologic, hepatic and renal functions; gave written informed consent prior to registration
Exclusion criteria
Exclusion criteria: Prior chemotherapy; unmeasurable disease; pregnancy and breastfeeding; CNS metastases; active infection and unhealing wounds, hepatic and renal functions deficiency; serious cardio-cerebrovascular disease such as coronary heart disease, unstable angina pectoris, myocardial infarction, cardiac arrhythmias, cerebral infarction and haemorrhage or psychiatric illness that would have affected compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progession-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;toxicity;response rate; | — |
Countries
China
Contacts
Public ContactZheng-Tao Zhou
Outcome results
None listed